Published in J Nutr on December 01, 2004
The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol (2007) 3.68
Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res (2007) 3.43
Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett (2008) 1.42
Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol (2006) 1.24
Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci (2008) 1.11
Regulation of microRNAs by natural agents: new strategies in cancer therapies. Biomed Res Int (2014) 1.06
Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer (2011) 1.04
Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3'-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol (2009) 1.01
Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr (2011) 1.00
Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem (2013) 0.96
3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol (2012) 0.96
Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm Drug Dispos (2011) 0.90
Epigenetic modifications of Nrf2 by 3,3'-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. AAPS J (2013) 0.88
Natural indoles, indole-3-carbinol and 3,3'-diindolymethane, inhibit T cell activation by staphylococcal enterotoxin B through epigenetic regulation involving HDAC expression. Toxicol Appl Pharmacol (2013) 0.87
Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation. Drug Metab Dispos (2015) 0.83
(3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer Prev Res (Phila) (2011) 0.82
Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol. Retrovirology (2009) 0.80
Recent progress on nutraceutical research in prostate cancer. Cancer Metastasis Rev (2014) 0.80
Anticancer Efficacy of Polyphenols and Their Combinations. Nutrients (2016) 0.80
Mechanisms and therapeutic implications of cell death induction by indole compounds. Cancers (Basel) (2011) 0.79
The effect of indole-3-carbinol on PIN1 and PIN2 in Arabidopsis roots. Plant Signal Behav (2015) 0.75
2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice. Toxicol Appl Pharmacol (2016) 0.75
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res (2006) 2.99
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res (2007) 2.71
miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells (2009) 2.64
Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One (2010) 2.63
Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther (2006) 2.44
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett (2011) 2.24
Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol (2010) 2.15
Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) (2011) 2.10
Multi-targeted therapy of cancer by genistein. Cancer Lett (2008) 2.02
Soy isoflavones and cancer prevention. Cancer Invest (2003) 2.02
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat (2010) 1.98
Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem (2011) 1.94
Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem (2010) 1.93
Retracted Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer (2006) 1.89
Emerging role of Notch in stem cells and cancer. Cancer Lett (2008) 1.88
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells (2008) 1.78
The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets (2010) 1.75
Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res (2006) 1.65
Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev (2009) 1.63
Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat (2010) 1.61
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta (2010) 1.59
NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol (2008) 1.59
Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res (2008) 1.59
Retracted FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat (2009) 1.57
Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res (2007) 1.56
Retracted Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer (2006) 1.44
Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta (2010) 1.42
Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett (2009) 1.42
Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev (2002) 1.40
Cellular signaling perturbation by natural products. Cell Signal (2009) 1.36
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One (2012) 1.33
Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res (2009) 1.32
Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene (2003) 1.31
The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29
Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res (2006) 1.28
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci (2008) 1.24
Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol (2006) 1.24
Cell signaling pathways altered by natural chemopreventive agents. Mutat Res (2004) 1.23
Retracted Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer (2006) 1.22
Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem (2011) 1.21
Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One (2012) 1.18
The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem (2006) 1.18
Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res (2013) 1.16
Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res (2012) 1.14
MicroRNA and Cancer: Tiny Molecules with Major Implications. Curr Genomics (2008) 1.13
Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev (2009) 1.13
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem (2007) 1.12
Total synthesis and structural elucidation of azaspiracid-1. Final assignment and total synthesis of the correct structure of azaspiracid-1. J Am Chem Soc (2006) 1.12
The role of isoflavones in cancer chemoprevention. Front Biosci (2004) 1.12
Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. PLoS One (2011) 1.11
Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci (2008) 1.11
Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res (2012) 1.10
Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr Cancer (2004) 1.09
Total synthesis of apoptolidin: construction of enantiomerically pure fragments. J Am Chem Soc (2003) 1.09
Structural revision and total synthesis of azaspiracid-1, part 1: intelligence gathering and tentative proposal. Angew Chem Int Ed Engl (2004) 1.08
Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate (2014) 1.07
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol (2013) 1.07
Retracted Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer (2006) 1.05
Total synthesis of the proposed azaspiracid-1 structure, part 1: construction of the enantiomerically pure C1-C20, C21-C27, and C28-C40 fragments. Angew Chem Int Ed Engl (2003) 1.05
Total synthesis of apoptolidin: completion of the synthesis and analogue synthesis and evaluation. J Am Chem Soc (2003) 1.05
PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets (2009) 1.04
Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One (2012) 1.02
FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm Res (2010) 1.01
Total synthesis of the proposed azaspiracid-1 structure, part 2: coupling of the C1-C20, C21-C27, and C28-C40 fragments and completion of the synthesis. Angew Chem Int Ed Engl (2003) 1.01
Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression. Curr Stem Cell Res Ther (2010) 1.00
The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev (2010) 1.00
Notch signaling proteins: legitimate targets for cancer therapy. Curr Protein Pept Sci (2010) 0.98
Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One (2012) 0.98
Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res (2006) 0.98
Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res (2011) 0.97
Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol Cancer Ther (2012) 0.97
Total synthesis and structural elucidation of azaspiracid-1. Synthesis-based analysis of originally proposed structures and indication of their non-identity to the natural product. J Am Chem Soc (2006) 0.97
Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des (2010) 0.97
Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem (2013) 0.96
Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol (2009) 0.96
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. J Cell Physiol (2007) 0.95
Rapid pulmonary fibrosis induced by acute lung injury via a lipopolysaccharide three-hit regimen. Innate Immun (2009) 0.90
Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets (2012) 0.88
Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment. Anticancer Agents Med Chem (2013) 0.87
Regulating miRNA by natural agents as a new strategy for cancer treatment. Curr Drug Targets (2013) 0.87
Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer (2006) 0.86
Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells. J Nutr (2003) 0.86
Evidence for reprogramming global gene expression during zinc deficiency in the HUT-78 cell line. Nutrition (2006) 0.84
Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells Dev (2014) 0.83
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103). J Med Chem (2009) 0.83
Targeting CSC-related miRNAs for cancer therapy by natural agents. Curr Drug Targets (2012) 0.83
The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent. Biochim Biophys Acta (2011) 0.82
Perspectives on the role of isoflavones in prostate cancer. AAPS J (2013) 0.82
Quantitative chemiluminescent immunoassay for NF-kappaB-DNA binding activity. J Immunoassay Immunochem (2005) 0.81
Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. Curr Stem Cell Res Ther (2014) 0.81
Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors. Bioorg Med Chem Lett (2008) 0.81
Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals. Mol Nutr Food Res (2013) 0.81
Novel targets for prostate cancer chemoprevention. Endocr Relat Cancer (2010) 0.80